信邦制药
(002390)
| 流通市值：52.82亿 | | | 总市值：53.26亿 |
| 流通股本：19.28亿 | | | 总股本：19.44亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,466,968,985.57 | 1,263,351,831.76 | 5,619,564,836.88 | 4,266,285,288.11 |
| 营业收入 | 2,466,968,985.57 | 1,263,351,831.76 | 5,619,564,836.88 | 4,266,285,288.11 |
| 二、营业总成本 | 2,327,110,195.38 | 1,191,141,535.16 | 5,295,462,160.32 | 4,026,405,575.21 |
| 营业成本 | 2,067,471,873.16 | 1,058,663,782.76 | 4,627,837,535.88 | 3,522,175,511.29 |
| 税金及附加 | 14,131,602.74 | 6,224,223.9 | 39,714,117.43 | 32,382,910.15 |
| 销售费用 | 70,284,858.57 | 33,638,345.28 | 253,710,732.31 | 196,038,993.09 |
| 管理费用 | 166,049,440.65 | 87,980,491.39 | 355,953,371.75 | 260,409,452.14 |
| 研发费用 | 4,353,628.61 | 1,949,183.11 | 5,796,252.22 | 4,292,649.11 |
| 财务费用 | 4,818,791.65 | 2,685,508.72 | 12,450,150.73 | 11,106,059.43 |
| 其中:利息费用 | 6,335,901.93 | 3,318,023.62 | 18,451,423.54 | 16,204,898.27 |
| 其中:利息收入 | 1,927,900.24 | 829,700.42 | 6,820,730.88 | 5,703,181.91 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 18,116,460.74 | 1,034,803.27 | 19,740,275.61 | 266,213.34 |
| 资产处置收益 | -524,452.91 | -636,285.32 | -484,633.96 | 85,864.27 |
| 资产减值损失(新) | - | - | -21,674,969.11 | - |
| 信用减值损失(新) | -7,110,646.32 | 2,178,362.06 | -90,768,242.43 | -8,110,037.85 |
| 其他收益 | 4,890,890.93 | 1,027,295.7 | 6,362,920.17 | 3,280,069.18 |
| 四、营业利润 | 155,231,042.63 | 75,814,472.31 | 237,278,026.84 | 235,401,821.84 |
| 加:营业外收入 | 3,142,575.94 | 2,191,487.47 | 17,930,632.31 | 1,337,418.29 |
| 减:营业外支出 | 4,644,146.48 | 1,734,692.46 | 25,243,923.54 | 11,511,838.22 |
| 五、利润总额 | 153,729,472.09 | 76,271,267.32 | 229,964,735.61 | 225,227,401.91 |
| 减:所得税费用 | 17,606,043.77 | 11,713,745.97 | 38,169,136.08 | 24,450,229.75 |
| 六、净利润 | 136,123,428.32 | 64,557,521.35 | 191,795,599.53 | 200,777,172.16 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 136,123,428.32 | 64,557,521.35 | 191,795,599.53 | 200,777,172.16 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 99,586,277.81 | 48,656,499.25 | 120,285,770.05 | 152,324,953 |
| 少数股东损益 | 36,537,150.51 | 15,901,022.1 | 71,509,829.48 | 48,452,219.16 |
| 扣除非经常损益后的净利润 | 76,636,127.5 | 47,145,196.25 | 87,111,687.33 | 156,845,693.05 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.05 | 0.03 | 0.06 | 0.08 |
| (二)稀释每股收益 | 0.05 | 0.03 | 0.06 | 0.08 |
| 八、其他综合收益 | -24,162,915.62 | - | 72,929,458.43 | - |
| 归属于母公司股东的其他综合收益 | -24,162,915.62 | - | 72,929,458.43 | - |
| 九、综合收益总额 | 111,960,512.7 | 64,557,521.35 | 264,725,057.96 | 200,777,172.16 |
| 归属于母公司股东的综合收益总额 | 75,423,362.19 | 48,656,499.25 | 193,215,228.48 | 152,324,953 |
| 归属于少数股东的综合收益总额 | 36,537,150.51 | 15,901,022.1 | 71,509,829.48 | 48,452,219.16 |
| 公告日期 | 2026-08-28 | 2026-04-29 | 2026-04-21 | 2025-10-29 |
| 审计意见(境内) | | | 标准无保留意见 | |